GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

The company is headquartered in London, UK with labs in Cambridge, UK. In January 2025, Alchemab announced an agreement with Eli Lilly and Company.

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly to develop and market ATLX-1282, a therapy candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of up to $250m over the next eight years by Lilly, to expedite innovation ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and ...

Eli Lil­ly is set to pay up to $415 million in an ALS deal with Alchemab Therapeutics. Independent proxy advisory firm ISS recommended Acelyrin stockholders vote in favor of the proposed transaction ...